Overlapping peptide-binding specificities of HLA-B27 and B39 - Evidence for a role of peptide supermotif in the pathogenesis of spondylarthropathies

被引:0
|
作者
Sobao, Y
Tsuchiya, N
Takiguchi, M
Tokunaga, K
机构
[1] Univ Tokyo, Grad Sch Med, Dept Human Genet, Bunkyo Ku, Tokyo 1130033, Japan
[2] Yokohama City Univ, Yokohama, Kanagawa 232, Japan
[3] Kumamoto Univ, Kumamoto, Japan
来源
ARTHRITIS AND RHEUMATISM | 1999年 / 42卷 / 01期
关键词
D O I
10.1002/1529-0131(199901)42:1<175::AID-ANR21>3.0.CO;2-7
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective, Previous studies indicated the increase of HLA-B39 among HLA-B27 negative patients with spondylarthropathies (SpA). This study was performed to examine whether the natural ligands of HLA-B27 are capable of binding to HLA-B39. Methods. Peptides were synthesized according to the sequences of known natural ligands of HLA-B27 or B39 and were tested for their binding to HLA-B*3901 and B*2705 by quantitative peptide binding assay, using a TAP-deficient RMA-S cell Line transfected with human beta(2)-microglobulin and HLA class I heavy chain genes. Results. Four of the 10 HLA-B27 binding peptides significantly bound to HLA-B*3901, AU 4 peptides had hydrophobic/aromatic amino acids (Leu or Phe) at the C-terminus. In contrast, peptides with basic residues (Lys, Arg) or Tyr at the C-terminus did not bind to B*3901, In parallel experiments, 1 of the 2 natural ligands of HLA-B"3901 was found to bind to B*2705, Conclusion, A subset of natural HLA-B27 ligands was capable of binding to B*3901, In addition to Arg at position 2 (Arg(2)), hydrophobic/aromatic C-terminal residues, such as Leu or Phe, seemed to be crucial for the cross-specificity. These results suggested that HLA-B27 and B39 recognize overlapping peptide repertoires, supporting the hypothesis that the peptides presented by both of these class I antigens play a role in the pathogenesis of SpA.
引用
收藏
页码:175 / 181
页数:7
相关论文
共 50 条
  • [1] Overlapping peptide-binding specificities of HLA-B27 and B39. Evidence for a role of peptide supermotif in the pathogenesis of spondylarthropathies.
    Tsuchiya, N
    Sobao, Y
    Takiguchi, M
    Tokunaga, K
    ARTHRITIS AND RHEUMATISM, 1998, 41 (09): : S287 - S287
  • [2] PEPTIDE MOTIFS OF HLA-B38 AND B39 MOLECULES
    FALK, K
    ROTZSCHKE, O
    TAKIGUCHI, M
    GNAU, V
    STEVANOVIC, S
    JUNG, G
    RAMMENSEE, HG
    IMMUNOGENETICS, 1995, 41 (2-3) : 162 - 164
  • [3] THE PEPTIDE BINDING-SPECIFICITY OF HLA-B27 SUBTYPES
    TANIGAKI, N
    FRUCI, D
    VIGNETI, E
    STARACE, G
    ROVERO, P
    LONDEI, M
    BUTLER, RH
    TOSI, R
    IMMUNOGENETICS, 1994, 40 (03) : 192 - 198
  • [4] DIFFERENCES IN PEPTIDE-BINDING SPECIFICITY OF 2 ANKYLOSING SPONDYLITIS-ASSOCIATED HLA-B27 SUBTYPES
    FRUCI, D
    BUTLER, RH
    GRECO, G
    ROVERO, P
    PAZMANY, L
    VIGNETI, E
    TOSI, R
    TANIGAKI, N
    IMMUNOGENETICS, 1995, 42 (02) : 123 - 128
  • [5] MODULATION OF PEPTIDE BINDING BY HLA-B27 POLYMORPHISM IN POCKETS A AND B, AND PEPTIDE SPECIFICITY OF B(ASTERISK)2703
    VILLADANGOS, JA
    GALOCHA, B
    GARCIA, F
    ALBAR, JP
    DECASTRO, JAL
    EUROPEAN JOURNAL OF IMMUNOLOGY, 1995, 25 (08) : 2370 - 2377
  • [6] Definition of an HLA-A3-like supermotif demonstrates the overlapping peptide-binding repertoires of common HLA molecules
    Sidney, J
    Grey, HM
    Southwood, S
    Celis, E
    Wentworth, PA
    delGuercio, MF
    Kubo, RT
    Chesnut, RW
    Sette, A
    HUMAN IMMUNOLOGY, 1996, 45 (02) : 79 - 93
  • [7] The pathogenesis of HLA-B27 arthritis: Role of HLA-B27 in bacterial defense
    Ikeda, M
    Yu, DTY
    AMERICAN JOURNAL OF THE MEDICAL SCIENCES, 1998, 316 (04): : 257 - 263
  • [8] IMMUNOGENETICS OF THE SERONEGATIVE SPONDYLARTHROPATHIES - PATHOGENETIC ROLE OF HLA-B27
    HERMANN, E
    ZUMBUSCHENFELDE, KHM
    AKTUELLE RHEUMATOLOGIE, 1994, 19 (03) : 77 - 83
  • [9] HLA-B27 AND THE HYPOTHESIS OF THE ARTHRITOGENIC PEPTIDE
    CORNELIS, F
    BELL, J
    REVUE DU RHUMATISME, 1994, 61 (03): : 147 - 149
  • [10] THE PEPTIDE-BINDING SPECIFICITY OF HLA-B27 SUBTYPE (B-ASTERISK-2705) ANALYZED BY THE USE OF POLYALANINE MODEL PEPTIDES
    FRUCI, D
    GRECO, G
    VIGNETI, E
    TANIGAKI, N
    BUTLER, RH
    TOSI, R
    HUMAN IMMUNOLOGY, 1994, 41 (01) : 34 - 38